Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
2.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
3.
Study recommends new grading system for invasive squamous cell carcinoma of the lung
4.
Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.
5.
EMA OKs Two Treatments for Small Cell Lung Cancer
1.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
2.
A Visual Guide to Understanding Breast Cancer Staging
3.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
4.
Exploring the Impact of Adrenal Myelolipoma on the Human Body
5.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Efficient Management of First line ALK-rearranged NSCLC - Part V
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation